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Summary
Personalized therapy of breast cancer is optimal therapeutic approach to the patient, taking into consideration his 
personal characteristics, as well as clinical characteristics of the malignant disease, involving pathohistological and molecu-
lar abnormalities of certain tumor. With the development of molecular oncology methods, genetic profi ling of each indi-
vidual tumor is possible. Beside the major subtypes of breast carcinoma based on steroide receptors, Ki-67 proliferative 
 index, and HER-2 receptors, numerous genetic subtypes of breast cancer have been found, due to enormous genetic hetero-
geneity and instability of tumor cells. Some of genetic changes are considered as driving genes, resulting in dysregulations 
ofcrucial signaling transduction pathways involving in cell proliferation, angiogenesis, apoptosis, invasion or metastasis. 
Certain components of signaling transduction pathways can be targeted molecules of so called targeted biological therapy. 
Understanding of complexities of these dysregulated multiple intracellular signaling cascades in the tumor cells is essential 
for the developing of novel potential molecular therapeutic targets.
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PERSONALIZIRANI PRISTUP LIJEČENJU RAKA DOJKE
Sažetak
Personalizirana terapija karcinoma dojke obuhvaća optimalni terapijski pristup, uvažavajući pacijentove osobine i 
kliničke karakteristike maligne bolesti, uključujući patohistološke i molekularne abnormalnosti tumora. Razvojem metoda 
molekularne onkologije omogućeno je genetičko određivanje svakog individualnog tumora. Pored osnovnih podtipova 
karcinoma dojke temeljem izražajnosti steroidnih receptora, HER-2 receptora i čimbenika proliferacije Ki-67, a zbog velike 
heterogenosti i nestabilnosti genoma tumorskih stanica, nalaze se i brojni drugi podtipovi. Neke od tih genetičkih promjena 
smatraju se tz v. pokretačkim genimaodgovornim za poremećenu regulaciju ključnih signalnih puteva u stanici uključenih u 
staničnu proliferaciju, angiogenezu, apoptozu, invaziju ili metastaziranje. Određene komponente signalnih puteva su ciljne 
molekule tz v. ciljane biološke terapije. Razumijevanje složenosti mehanizama poremećenih prijenosa signala u tumorskim 
stanicama ključno je za razvoj novih mogućih meta ciljane biološke terapije karcinoma dojke.
KLJUČNE RIJEČI: rak dojke, prijenos signala u stanici, personalizirana terapija
The normal cells, as well as the tumor cells 
have capability to respondtothe numerous exter-
nal stimuli such as growth factors, hormons or cy-
tokines. This complex processes comprise recog-
nition on cellular mebrane by receptors, intracel-
lular signalling transduction pathways,activation 
of numerous transcription factors, and expression 
of diff erent genes. This is the way of cellular re-
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sponse to microenvironment, as well as regulation 
of cellular proliferation and diff erentiation (1). In 
this complex multifactorial nets of signaling trans-
duction pathways from cellular membrane to nu-
cleus, the crutial role have protein kynases, en-
zymes involved in methabolic pathways, protein 
phosphorilation, transport and activation, as well 
as in degradation of proteins. Changes in compo-
nents of signaling transduction pathways can re-
sult in malignant cell transformation. In normal 
cells signaling transduction pathway is precisly 
regulated. In tumor cells, crucial molecules of this 
complex signaling transduction pathways can be 
changed by diff erent mechanisms, envolving ex-
pression of some oncogenes, leading to abnormal 
signaling transduction pathways, inhibition of 
apoptosis, uncontrolled tumor cells proliferation, 
angiogenesis, tumor invasion and metastasizing 
(2). Activation of some oncogenes (e.g. ErbB2, 
PI3K, Akt, Myc,), or loss of function of some tu-
mor supressor genes (TP53, or PTEN),resulting in 
changes in signalling pathways sach as PI3K/Akt/
mTOR, or raf/MEK/ERK are implicated to be in-
volved in carcinogenesis of breast cancer(3). Cer-
tain components of signalling transduction path-
ways can be target molecules of so called targeted 
biological therapy. Understanding of complexities 
of these dysregulated multiple intracellular sig-
nalling cascades in the tumor cells is essential for 
the developing of novel potential molecular thera-
peutic targets (4).
Personalized therapy of malignant deseases, 
including breast cancer is, according to the defi ni-
tion, optimal therapeutic approach to the patient, 
taking into consideration his individual, personal 
characteristics (including genetic), as well as clini-
cal characteristics of the malignant disease, in-
volving pathohystological and molecular abnor-
malities of certain tumor. With the devolopment 
of molecular oncology methods, especially with 
DNA microarray analyses, genetic profi ling of 
each individual tumor is possible. Two biggest in-
ternational projects of systematic genomic analy-
ses of tumor samples are currently ongoing: The 
Cancer Genome Atlas – NIH project in USA, and 
International Cancer Genomic Consortium in the 
rest of the world (3). With these molecular genetic 
analyses, numerous genetic changes in breast can-
cer have been found, some of them are considered 
as driving genes, but the real role of some genetic 
changes in carcinogenesis remans to be deter-
mined (5).
According to the recommendations of St. 
Gallen conference (St. Gallen International Expert 
Consensus on the Primary Therapy of Early Breast 
Cancer, 2013) it is obligatory to determine major 
subtypes of breast cancer on the basis of immuno-
hystochemical analysis of estrogene and proges-
terone receptors, HER-2 receptors and Ki-67 pro-
liferation index on the tumor tissue samples (6). 
The therapeutic basis for luminal A and luminal B 
subtypes of steroide receptor positive breast can-
cer is hormonal therapy, imunotherapy should be 
included in the treatment of HER 2 positive sub-
types, while chemotherapy is still the basis for 
treatment triple negative (basal like) subtypes of 
breast cancer. However, molecular analyses of in-
dividual breast carcinoma tissues revealed that 
each of these subtypes can comprise futher new 
genetic subtypes of tumors which can deff er in 
prognosis and response to the therapy. According 
to numerous studies in the fi eld of breast cancer, a 
great therapeutic problem in this desease is pro-
nounced heterogeneity of tumor cells among ap-
parently similar tumors, as well as diff ent tumor 
clones in even one tumor. Tumor genome is very 
unstable, prone to numerous changes and muta-
tions, even during therapy, which can lead to in-
duction of diff erent mechanisms of resistance and 
survival of mutated clones of tumor cells (3).
Hormonal therapy of steroid receptor posi-
tive breast cancer is one of the oldest and most 
succesful personalyzed therapeutic approach. With 
hormonal therapy steroid receptor expressionon 
tumor cells is modulated or downregulatedand/or 
hormone synthesis is blocked, resulting in de-
creased activation of estrogen signaling pathway. 
However, it has been shown that there is possi-
bility of parallel activation of diff erent signaling 
transduction pathways in breast cancer cells to-
gether with steroide receptor pathway (e.g. sig-
naling pathways of EGFR, and PI3K/Akt/mTOR) 
which can be activated in resistance to hormonal 
therapy (7). We block one signaling pathway with 
targeted therapy, but tumor cells activate diff erent 
compensatory mechanisms and other numerous 
signaling pathways. This is the basis for therapeu-
tic concept of necessity of parallel blocking of dif-
ferent signaling pathways – such as hormonal 
therapy together with mTOR inhibition in breast 
cancer patients (e.g. BOLERO-2 clinical trial of ad-
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dition of mTOR inhibitor everolimus to aromata-
se inhibitor exemestan in the treatment of hor-
mone receptor positive advanced breast cancer 
patients) (8,9).
Immunotherapy is the mainstain for the treat-
ment of HER-2 positive breast cancer (10). How-
ever, it has been shown that signifi cant percent of 
HER-2 positive breast cancer does not respond to 
immunotherapy (11). Diff erent expression of 
TOPO2A enzyme in the group of HER 2 positive 
breast cancer could be one of the reasons of het-
erogeneity. Tumors with mutation of HER-
2,instead of HER-2 amplifi cation could be another 
subgroup (12). Second and third generations of 
anti-HER-2 therapies are in clinical studies, as 
well as so called dual blocking of ErbB2 pathway 
(e.g. anti HER2/neu receptor antibody together 
with tyrosine kinase inhibitors, as well as diff erent 
combinations of chemotherapy, HER-2 blocking 
and blocking of some other signalling pathways 
by targeted agents (13). A recent molecular anly-
ses of triple negative breast cancer (TNBC) re-
vieled that diff erent subgroups can be identifi ed, 
defi ned by mesenchymal features, immune sys-
tem-related genes, DNA damage response genes 
and activated androgen receptor signalling (14).
Potential novel therapeutic targets will be defi ned 
on the basis of this heterogeneity, like PARP in-
hibitors in defi ciencies in the BRCA1 gene path-
way (13).
CONCLUSION
In conclusion, we can say that reliable prog-
nostic and predictive parametars for breast can-
cer, or biomarkers for identifi cation of diff erent 
tumor subpopulations are still widely needed 
(1,15). A great progress on the way of personaliza-
tion in the therapy of breast cancer has been al-
ready achieved, but because of enormous genetic 
instability and heterogeneity, breast cancer is still 
largely unknown and the subject of numerous in-
vestigations.
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